LINC01116 Binds CPS1 to Regulate Urea Cycle Function, Thereby Promoting Progression and Chemoresistance in Osteosarcoma

Why It Matters

Targeting the LINC01116‑CPS1 pathway could curb metastasis and overcome cisplatin resistance, addressing a critical unmet need in pediatric bone cancer treatment.

Key Takeaways

• LINC01116 overexpressed in metastatic osteosarcoma.
• LINC01116 binds CPS1, modulating urea cycle.
• Silencing LINC01116 reduces tumor growth in mice.
• Disrupting LINC01116/CPS1 lowers citrulline levels.
• CPS1 knockdown increases cisplatin sensitivity.

Pulse Analysis

Osteosarcoma remains the leading primary bone malignancy among children and adolescents, yet survival rates have plateaued due to frequent metastasis and chemoresistance. Recent research highlights metabolic reprogramming as a driver of aggressive behavior, with long non‑coding RNAs (lncRNAs) emerging as key regulators of tumor metabolism. By integrating transcriptomic profiling with functional assays, investigators identified LINC01116 as a potent oncogenic lncRNA that is consistently elevated in metastatic lesions, positioning it as a biomarker of disease progression.

Mechanistically, LINC01116 exerts its pro‑tumorigenic effect by physically interacting with carbamoyl‑phosphate synthase 1 (CPS1), the rate‑limiting enzyme of the hepatic urea cycle. Chromatin isolation by RNA purification coupled with mass spectrometry (ChIRP‑MS) confirmed this binding, and subsequent knockdown experiments demonstrated a drop in intracellular citrulline, a direct readout of urea‑cycle activity. The attenuation of the LINC01116/CPS1 axis not only curbed cell proliferation in culture but also reduced tumor burden in mouse xenografts, underscoring the functional relevance of metabolic control in osteosarcoma growth.

Clinically, the LINC01116‑CPS1 pathway offers a two‑fold therapeutic opportunity. First, disrupting the axis impairs a metabolic niche that supports metastatic expansion. Second, CPS1 silencing markedly enhances sensitivity to cisplatin, suggesting that combination strategies targeting both the lncRNA‑protein interaction and conventional chemotherapy could overcome drug resistance. As precision oncology advances, integrating metabolic inhibitors with existing regimens may improve outcomes for patients battling high‑risk osteosarcoma.